Binge eating disorder (BED) is the most prevalent eating disorder, characterized by recurrent episodes of consuming large amounts of food rapidly while feeling a loss of control, without the compensatory behaviors seen in bulimia nervosa. It is closely linked with obesity, depression, and metabolic complications, and substantially impairs quality of life. Many people live with BED for years before receiving a diagnosis or treatment.
What's actually going on in research
Cognitive behavioral therapy (CBT) is the most evidence-based psychological treatment and achieves remission in a meaningful portion of patients. Lisdexamfetamine is the only FDA-approved medication specifically for BED, reducing binge frequency. Newer research is exploring GLP-1 receptor agonists — which powerfully reduce appetite and compulsive eating — as well as topiramate, naltrexone combinations, and digital and app-based CBT delivery to reach the many who cannot access in-person care.
GLP-1 receptor agonists
GLP-1 agonists such as semaglutide and liraglutide are being studied in BED, with early evidence suggesting meaningful reductions in binge frequency and body weight, though trials are ongoing.
Digital CBT delivery
App-based and telehealth CBT programs are in trials to expand access to evidence-based psychological care for people with BED who face barriers to traditional in-person therapy.
Combination pharmacotherapy
Naltrexone/bupropion and topiramate-based combinations are being evaluated for their effects on binge episode frequency and the emotional drivers of loss-of-control eating.
What to know before you search
Eligibility is generally based on DSM-5 BED diagnosis, binge episode frequency, and absence of compensatory purging behaviors.
What types of trials are currently open
- GLP-1 agonist trials — Testing semaglutide and related agents for reduction of binge episodes and associated weight gain.
- Digital therapy trials — Evaluating app-based and telehealth cognitive behavioral therapy as scalable first-line treatments.
- Combination medication trials — Studying naltrexone/bupropion, topiramate, and other drug combinations for binge frequency reduction.
- Neurostimulation trials — Investigating transcranial magnetic stimulation and related approaches targeting food reward circuits.
- Integrated care trials — Testing combined psychological and medical treatment models that address both eating disorder and weight outcomes.
Recently added Binge Eating Disorder trials
Cognitive Evaluation of Patients With Eating Disorders
The goal of this cross - sectional observational study is to improve understanding of the psychological and cognitive characteristics of Feeding and Eating Disorders (FEDs), a group of conditions that represent a growing public health concern due to their significant impact on physical health, emotional well-being, and everyday functioning. Within this broader diagnostic category, particular attention is given to Avoidant/Restrictive Food Intake Disorder (ARFID), a diagnosis introduced in the DSM-5 and still relatively underexplored compared to other feeding and eating disorders. Despite its clinical relevance, ARFID remains less well understood in terms of its underlying cognitive and psychological mechanisms. Individuals with ARFID often experience severe food avoidance or restriction that is not driven by weight or shape concerns, but rather by sensory sensitivities, fear of negative consequences of eating, or a lack of interest in food. For this reason, investigating ARFID can offer important insights into the diversity of mechanisms involved in feeding and eating disorders as a whole. The study has two main objectives. The first objective is to examine the cognitive profile of individuals with ARFID, with a specific focus on autistic traits and cognitive flexibility, as previous research suggests potential overlaps between ARFID and neurodevelopmental conditions such as Autism Spectrum Disorders. Cognitive flexibility refers to the ability to adapt thoughts and behaviors in response to changing situations, and reduced flexibility may contribute to rigid eating patterns and food avoidance. The second objective is to explore the role of body representation (how individuals perceive and mentally represent their own body) and inhibitory control (the ability to regulate or suppress automatic responses) in shaping the cognitive and behavioral features of ARFID and other feeding and eating disorders. These processes may help distinguish ARFID from other diagnoses and clarify shared and disorder-specific mechanisms across the FED spectrum. The study involves adult participants of all genders, including individuals diagnosed with ARFID, anorexia nervosa, and bulimia nervosa, as well as healthy control participants without a history of feeding or eating disorders. This design allows meaningful comparisons between different diagnostic groups and with the general population. The main questions the study aims to answer are: Do individuals with ARFID show a distinct cognitive profile, particularly in terms of autistic traits and cognitive flexibility, compared to individuals with other feeding and eating disorders and healthy controls? How do body representation and inhibitory control contribute to differences in eating-related behaviors across feeding and eating disorders? Are there differences in brain activity associated with implicit, automatic attitudes toward food in individuals with feeding and eating disorders compared to healthy individuals? Where comparison groups are included, researchers will compare participants with ARFID, anorexia nervosa, bulimia nervosa, and healthy controls to examine differences in cognitive functioning, psychological characteristics, and neural responses related to food processing. Participants will be asked to take part in a series of non-invasive and well-established research activities, designed to be accessible and safe. These include: Completing self-report questionnaires assessing autistic traits, body image perception, and general psychological well-being; Performing computer-based tasks that assess cognitive flexibility and decision-making; Completing behavioral tasks designed to measure inhibitory control and automatic associations with food-related stimuli;
COR Protocol for the Treatment of Binge Eating in Chilean Adults (COR)
The goal of this clinical study is to learn whether a brief online psychological program called COR can be delivered in a feasible and acceptable way for adults who experience recurrent binge eating. The main questions this study aims to answer are: * Is the COR program acceptable to participants, in terms of satisfaction, adherence, and dropout rates? * Is the COR program feasible to deliver online, including recruitment, retention, and completion of sessions and questionnaires? * Do participants show preliminary changes over time in binge eating-related distress and emotional well-being? Participants in this study are adults who experience recurrent episodes of binge eating. They will take part in an individual online intervention that includes eight weekly sessions, a brief pre-session, and a follow-up session one month after the end of treatment. During the study, participants will: * Attend weekly online sessions focused on understanding binge eating, emotions, and the relationship with food and the body * Practice simple exercises to help manage emotional distress and food-related urges * Complete short questionnaires before, during, and after the intervention to describe their experiences The information from this study will help researchers understand whether this type of intervention can be used in future, larger studies and in real-world clinical settings.
Find Binge Eating Disorder trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.